Australian Lung Screen Trial for people at risk of developing lung cancer living in diverse geographic and socioeconomic Australian locations.
- Conditions
- ung cancerLung cancerCancer - Lung - Non small cellCancer - Lung - Small cellPublic Health - Health service research
- Registration Number
- ACTRN12623001305617
- Lead Sponsor
- The University of Queensland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1500
Male and Female
Aged 50-80 years.
ECOG performance status of 0 or 1
Capable of providing, informed consent for screening procedures (low dose spiral CT)
Meets the PLCOm2012 criteria with risk score equal to or greater than 1.51% over 6 years, aged 55 to 74 years, or Australian Medical Services Committee (MSAC) criteria aged 50 to 70 years who have a history of cigarette smoking of at least 30 pack-years, and, if former smokers, quit within the previous 10 years, or US Preventative Services Task Force (USPSTF) criteria of Adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or quit within the past 15 years
Clinical symptoms suspicious for lung cancer e.g., haemoptysis, chest pain, weight loss
Any medical condition, such as severe heart disease (e.g., unstable angina, chronic congestive heart failure), acute or chronic respiratory failure, home oxygen therapy, bleeding disorder, that in the opinion of the investigator could jeopardize the subject’s safety during participation in the study or unlikely to benefit from screening due to shortened life-expectancy from the co-morbidities.
Have been previously diagnosed with lung cancer.
Have had other non-curatively treated cancer outside the lung.
Pregnancy.
Pneumonia or bronchitis requiring antibiotic treatment within the last 12 weeks.
Unwilling to have a spiral chest CT.
Chest CT within 2 years
Does not fit into CT scanner table due to gross obesity.
Cannot lie on CT scanning table on the back with arms over the head.
Received chemotherapy or cytotoxic drugs within the last 6 months.
Unwilling to provide consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method